 |
 |
 |
|
 |
articles < press << main |
 |
 |
|
|
|
|
|
|
|
| date | | | | title / topic / summary | sort by topic |
|---|
|
| 10/28/2004 | | | | Statin Drugs and Mechanism for Alzheimer's Explored in Large Group of New Scientific Studies
topic: Statins and Alzheimer's Disease
October 28, 2004: Exploring statin drugs and their
effect on the Alzheimer's disease process was a hot topic of scientific presentations at
the Society for Neuroscience's annual meeting at San Diego, California this week. The
potential of statins, a class of widely prescribed cholesterol-lowering drugs, in the
prevention of Alzheimer's disease has been shown in a number of large studies published in
Lancet and Archives of Neurology among others. Now new scientific studies are further
exploring how statins have an effect on the Alzheimer's disease process, increasing the
hope that these well-known safe drugs may provide a new treatment for patients with
Alzheimer's disease. |
| 10/22/2004 | | | | Nymox Issued U.S. Patent for Saliva Cholesterol Test
topic: R&D: Other Diagnostics
October 22, 2004: Nymox Pharmaceutical Corporation announced today that it has received notice of issuance of a new U.S. patent for a unique
method and device for using saliva to determine cholesterol levels. |
| 10/21/2004 | | | | Nymox TobacAlert™ To Be Available at CVS Pharmacies Across the U.S.
topic: Tobacco Exposure Tests
October 21, 2004: Nymox Pharmaceutical Corporation announced today that CVS, a leading retail pharmacy chain, will soon be making the
Company's TobacAlert™ product available in over 5,000 CVS/pharmacy stores
across the U.S. |
| 10/08/2004 | | | | Nymox Announces $13 Million Equity Financing
topic: Financial
October 8, 2004: Nymox Pharmaceutical Corporation announced
today that the Company has secured commitment for $13 million in private equity financing.
The funds will be used for general corporate purposes. The private placement of common
stock is with institutional investors and is priced at a 3% discount to the market price.
There are no warrants with the placement and no restrictions on other corporate financing. |
| 10/07/2004 | | | | Nymox Signs Licensing Agreement with Health Canada
topic: R&D: E coli and Other Antibacterial Treatments
October 7, 2004; Nymox Pharmaceutical Corporation announced today the signing of a licensing agreement with Health Canada for the licensing
of patent rights and technology for the treatment of deadly E. coli O157:H7
bacteria in cattle. The
licensing agreement is part of a collaboration with Dr. Roger Johnson and the Laboratory
for Foodborne Zoonoses in Guelph, Ontario for the research and development of novel animal
and related treatments for E. coli O157:H7, a bacteria implicated in
contamination of meat products and of drinking water supplies. |
| 10/05/2004 | | | | Nymox's TobacAlert™: A Simple, Cost-Effective Way of Measuring Second Hand Smoke
topic: Tobacco Exposure Tests
October 5, 2004: TobacAlert™, Nymox's unique proprietary tobacco exposure test, has been garnering attention in the media and on the Internet as non-smokers and parents are increasingly concerned about exposure to second hand smoke in public places and in the home. |
| 10/01/2004 | | | | Nymox Makes Steady Progress With Alzheimer's Products
topic: R&D: Alzheimer's Disease Treatments
October 1, 2004: Nymox Pharmaceutical Corporation has
developed and markets AlzheimAlert™, the only non-invasive test proven to help in the
diagnosis of AD; and has a healthy pipeline of drugs in development for AD. |
| 09/30/2004 | | | | Nymox Develops New Methods of Treating Deadly E. Coli Food Contamination
topic: R&D: E coli and Other Antibacterial Treatments
September 30, 2004: Nymox's proprietary NXC-4720 product for the treatment of potentially fatal E. coli
O157:H7 contamination has applications beyond treatment of meat at the processing stage,
according to Michael Munzar, MD, Medical Director of Nymox. E. coli O157 bacteria
can not only contaminate meat products such as ground beef but also public water supplies
that can become contaminated from run-off from cattle farming operations where there are
cattle harboring the deadly bacteria. |
| 09/29/2004 | | | | Nymox Files 6K Re Insider Stock Purchases
topic: Financial
September 29, 2004: Nymox announced today that the Company filed a Form 6K with the SEC detailing the stock
purchases of the Company's management and directors. As detailed in the filing, directors
and management have made zero sales of stock, and have bought in the open market a total
of 230,475 shares of Nymox stock since December 20, 2000. In the past twelve months,
management and directors bought 94,700 shares with no sales. |
| 09/23/2004 | | | | Statin Drugs For Alzheimer's Recognized as Emerging Indication
topic: Statins and Alzheimer's Disease
September 23, 2004: According to a new lead story in the September 13 2004
issue of Physician's Weekly, there is now considerable epidemiological evidence
suggesting that statins, a class of widely prescribed cholesterol-lowering drugs, can
reduce risk of Alzheimer's disease and possibly slow its progression. The story, “Statins: The Emerging Indications,” outlines the encouraging evidence and notes
that further large trials studying statins and Alzheimer's disease are now in progress. |
|